A multi-centre, randomized, parallel-group, single blind Phase II trial to evaluate the pharmacokinetics and PKPD relationship of trazodone after single and repeated oral doses in children from 2 to ≤ 17 years of age, suffering from insomnia, with autism, intellectual disability or attention deficit hyperactivity disorder (ADHD)
Latest Information Update: 02 Sep 2021
At a glance
- Drugs Trazodone (Primary)
- Indications Attention-deficit hyperactivity disorder; Autistic disorder; Insomnia; Mental retardation; Neurodevelopmental disorders
- Focus Pharmacokinetics
- Sponsors Angelini Group
- 13 May 2021 Status changed from recruiting to discontinued.
- 26 Dec 2019 New trial record